Pulmatrix Announces Positive Results From Initial Stage of Phase IB Clinical Study of PUR0200 in COPD Patients
LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix today announced the successful completion and positive results of the first part of a two-part Phase IB clinical study in chronic obstructive pulmonary disease (COPD) patients with their lead clinical candidate PUR0200. PUR0200 is a bronchodilator therapy for COPD and is the first small molecule product from the company's novel iSPERSEā¢ inhaled dry powder technology. The first part of the Phase 1B clinical trial evaluated the safety, tolerability and the pharmacokinetic/pharmacodynamic profile of single ascending doses of PUR0200 in patients with moderate COPD.
Help employers find you! Check out all the jobs and post your resume.